Literature DB >> 8413236

RFX1 is identical to enhancer factor C and functions as a transactivator of the hepatitis B virus enhancer.

C A Siegrist1, B Durand, P Emery, E David, P Hearing, B Mach, W Reith.   

Abstract

Hepatitis B virus gene expression is to a large extent under the control of enhancer I (EnhI). The activity of EnhI is strictly dependent on the enhancer factor C (EF-C) site, an inverted repeat that is bound by a ubiquitous nuclear protein known as EF-C. Here we report the unexpected finding that EF-C is in fact identical to RFX1, a novel transcription factor previously cloned by virtue of its affinity for the HLA class II X-box promoter element. This finding has allowed us to provide direct evidence that RFX1 (EF-C) is crucial for EnhI function in HepG2 hepatoma cells; RFX1-specific antisense oligonucleotides appear to inhibit EnhI-driven expression of the hepatitis B virus major surface antigen gene, and in transfection assays, RFX1 behaves as a potent transactivator of EnhI. Interestingly, transactivation of EnhI by RFX1 (EF-C) is not observed in cell lines that are not of liver origin, suggesting that the ubiquitous RFX1 protein cooperates with liver-specific factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8413236      PMCID: PMC364696          DOI: 10.1128/mcb.13.10.6375-6384.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Broad specificity of the hepatitis B enhancer function.

Authors:  E Elfassi
Journal:  Virology       Date:  1987-09       Impact factor: 3.616

2.  Interaction of a nuclear factor with the polyomavirus enhancer region.

Authors:  P Ostapchuk; J F Diffley; J T Bruder; B Stillman; A J Levine; P Hearing
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

3.  Methylated DNA-binding protein from human placenta recognizes specific methylated sites on several prokaryotic DNAs.

Authors:  R Y Wang; X Y Zhang; R Khan; Y W Zhou; L H Huang; M Ehrlich
Journal:  Nucleic Acids Res       Date:  1986-12-22       Impact factor: 16.971

4.  A protein from human placental nuclei binds preferentially to 5-methylcytosine-rich DNA.

Authors:  L H Huang; R Wang; M A Gama-Sosa; S Shenoy; M Ehrlich
Journal:  Nature       Date:  1984 Mar 15-21       Impact factor: 49.962

5.  Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei.

Authors:  J D Dignam; R M Lebovitz; R G Roeder
Journal:  Nucleic Acids Res       Date:  1983-03-11       Impact factor: 16.971

6.  Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.

Authors:  B B Knowles; C C Howe; D P Aden
Journal:  Science       Date:  1980-07-25       Impact factor: 47.728

7.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

8.  A bacteriophage T7 RNA polymerase/promoter system for controlled exclusive expression of specific genes.

Authors:  S Tabor; C C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

9.  A novel expression selection approach allows precise mapping of the hepatitis B virus enhancer.

Authors:  A Tognoni; R Cattaneo; E Serfling; W Schaffner
Journal:  Nucleic Acids Res       Date:  1985-10-25       Impact factor: 16.971

10.  A human hepatitis B viral enhancer element.

Authors:  Y Shaul; W J Rutter; O Laub
Journal:  EMBO J       Date:  1985-02       Impact factor: 11.598

View more
  36 in total

1.  Dimeric RFX proteins contribute to the activity and lineage specificity of the interleukin-5 receptor alpha promoter through activation and repression domains.

Authors:  A Iwama; J Pan; P Zhang; W Reith; B Mach; D G Tenen; Z Sun
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

Review 2.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  p140/c-Abl that binds DNA is preferentially phosphorylated at tyrosine residues.

Authors:  R Dikstein; R Agami; D Heffetz; Y Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

4.  Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions.

Authors:  N Jabrane-Ferrat; J D Fontes; J M Boss; B M Peterlin
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

5.  Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II.

Authors:  K Ueda; Y Wei; D Ganem
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Interactions of the transcription factors MIBP1 and RFX1 with the EP element of the hepatitis B virus enhancer.

Authors:  M Blake; J Niklinski; M Zajac-Kaye
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys.

Authors:  C S Lim; N Jabrane-Ferrat; J D Fontes; H Okamoto; M R Garovoy; B M Peterlin; C A Hunt
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

8.  The transcriptional activation and repression domains of RFX1, a context-dependent regulator, can mutually neutralize their activities.

Authors:  Y Katan; R Agami; Y Shaul
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

9.  Regulation of FGF1 gene promoter through transcription factor RFX1.

Authors:  Yi-Chao Hsu; Wei-Chih Liao; Chien-Yu Kao; Ing-Ming Chiu
Journal:  J Biol Chem       Date:  2010-02-26       Impact factor: 5.157

10.  Transcription factors RFX1/EF-C and ATF-1 associate with the adenovirus E1A-responsive element of the human proliferating cell nuclear antigen promoter.

Authors:  C Labrie; B H Lee; M B Mathews
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.